Amgen has filed to settle on undisclosed terms patent-infringement litigation involving both its Kanjinti and Mvasi biosimilars, having previously seen originator Genentech fail multiple times to block commercial sales of the products that were launched ‘at risk’.
Amgen and Genentech have filed jointly in the US to settle and dismiss cases for patent infringement brought by the Roche subsidiary over Amgen’s Kanjinti (trastuzumab-anns) and Mvasi (bevacizumab-awwb) biosimilars, just 24 hours after a US Court of Appeals denied Genentech a temporary restraining order over Amgen’s Avastin (bevacizumab) biosimilar.
An appeals court had also sided with Amgen over attempts by Genentech to secure a TRO against the Herceptin (trastuzumab)...
In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.
The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.
Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
